Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

Jagust W, Reed B, Mungas D, Ellis W, Decarli C.

Neurology. 2007 Aug 28;69(9):871-7.

PMID:
17724289
2.

FDG PET imaging in patients with pathologically verified dementia.

Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE.

J Nucl Med. 2000 Nov;41(11):1920-8.

3.

Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.

Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS.

BMC Neurol. 2009 Aug 12;9:41. doi: 10.1186/1471-2377-9-41.

4.

Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence.

Garibotto V, Borroni B, Kalbe E, Herholz K, Salmon E, Holtoff V, Sorbi S, Cappa SF, Padovani A, Fazio F, Perani D.

Neurology. 2008 Oct 21;71(17):1342-9. doi: 10.1212/01.wnl.0000327670.62378.c0.

PMID:
18936426
5.

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ.

J Nucl Med. 2008 Mar;49(3):390-8. doi: 10.2967/jnumed.107.045385. Epub 2008 Feb 20.

6.

Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.

Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, Matsuda H, Mori E.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9. Epub 2006 Mar 21.

PMID:
16550383
7.

Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.

Döbert N, Pantel J, Frölich L, Hamscho N, Menzel C, Grünwald F.

Dement Geriatr Cogn Disord. 2005;20(2-3):63-70. Epub 2005 May 20.

PMID:
15908747
8.

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia.

Degenhardt EK, Witte MM, Case MG, Yu P, Henley DB, Hochstetler HM, D'Souza DN, Trzepacz PT.

Psychosomatics. 2016 Mar-Apr;57(2):208-16. doi: 10.1016/j.psym.2015.12.002. Epub 2015 Dec 3.

9.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
10.

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S.

Brain. 2007 Oct;130(Pt 10):2616-35. Epub 2007 Aug 18.

PMID:
17704526
12.

PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.

13.

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.

Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME.

JAMA. 2001 Nov 7;286(17):2120-7.

PMID:
11694153
14.
15.

Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature.

Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S.

J Nucl Med. 2012 Jan;53(1):59-71. doi: 10.2967/jnumed.111.096578. Epub 2011 Dec 15. Review.

16.

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A.

J Nucl Med. 2005 Oct;46(10):1625-32.

17.

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.

Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ.

Neurology. 2007 Apr 10;68(15):1205-12.

PMID:
17420404
18.

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A.

Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13. Epub 2003 May 23.

PMID:
12764551
19.

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ.

Neurology. 2005 Jun 14;64(11):1860-7.

PMID:
15955934
20.

Positron emission tomography metabolic correlates of apathy in Alzheimer disease.

Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL.

Arch Neurol. 2007 Jul;64(7):1015-20.

PMID:
17620493

Supplemental Content

Support Center